Measurement of dissociative states with the Clinician‐Administered Dissociative States Scale (CADSS)
J. Douglas Bremner, John H. Krystal, Frank W. Putnam, Steven M. Southwick, Charles R. Marmar, Dennis S. Charney, Carolyn M. Mazure
Journal of Traumatic Stress 1998 DOI: 10.1023/a:1024465317902 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Validation study Peer reviewed |
|---|---|
| Population | Patients with dissociative disorders, patients with other psychiatric disorders, and healthy subjects |
| Keywords | Dissociative disorders Inter-rater reliability Dissociation chemistry Construct validity Dissociative experiences scale Internal consistency Psychometrics Clinical psychology Test validity Rating scale Developmental psychology Psychosis |
| Citations | 826 |
| Key points | The CADSS demonstrated good interrater reliability and construct validity, and its scores discriminated patients with dissociative disorders from other groups. |
Abstract
The purpose of this study was to develop an instrument for the measurement of present-state dissociative symptoms, the Clinician Administered Dissociative States Scale (CADSS). Reported here are interrater reliability and internal consistency of the CADSS, validity as assessed by comparisons with other instruments for the assessment of dissociation, and sensitivity of the CADSS to discriminate patients with dissociative disorders from patients with other psychiatric disorders and healthy subjects. Initial analyses indicated good interrater reliability and construct validity for the CADSS. Scores on the CADSS discriminated patients with dissociative disorders from the other groups.
Citations in the library
Cited by 306
- Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial American Journal of Psychiatry August 28, 2013
- A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression Archives of General Psychiatry August 1, 2010
- Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study American Journal of Psychiatry May 21, 2019
- Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial Psychological Medicine June 15, 2018
- Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression JAMA Psychiatry June 5, 2019
and 301 more in the library